Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc H Scheetz

Showing results (91-100 of 222) with videos related to

Pageof 23
Sort By:
Antimicrobial Agents and Chemotherapy|April 23, 2014
Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coliNathaniel J Rhodes, Chad L Richardson, Ryan Heraty, et al.
International Journal of Antimicrobial Agents|July 3, 2017
Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' windowCristina Miglis, Nathaniel J Rhodes, Joseph L Kuti, et al.
Infection Control and Hospital Epidemiology|May 14, 2016
Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption MetricsNathaniel J Rhodes, Jamie L Wagner, Elise M Gilbert, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2006
Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stayKimberly K Scarsi, Joe M Feinglass, Marc H Scheetz, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2007
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumanniiMarc H Scheetz, Chao Qi, John R Warren, et al.
Clinical Pharmacology and Therapeutics|June 11, 2026
Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug DosingMarc H Scheetz, Thomas P Lodise, Nathaniel J Rhodes, et al.
Genome Announcements|March 12, 2016
Genome Sequences of Five Clinical Isolates of Klebsiella pneumoniaeL Letti Lopez, Brigida Rusconi, Heidi Gildersleeve, et al.
Diagnostic Microbiology and Infectious Disease|July 4, 2017
Factors contributing to vancomycin-resistant Enterococcus spp. horizontal transmission events: exploration of the role of antibacterial consumptionElise M Gilbert, Teresa R Zembower, Nathaniel J Rhodes, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 30, 2015
An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicityNathaniel J Rhodes, Joseph L Kuti, David P Nicolau, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2015
Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the HorseNathaniel J Rhodes, J Nicholas O'Donnell, Bryan D Lizza, et al.
Pageof 23

Showing results (91-100 of 222) with videos related to

Sort By:
Pageof 23
Antimicrobial Agents and Chemotherapy|April 23, 2014
Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coliNathaniel J Rhodes, Chad L Richardson, Ryan Heraty, et al.
International Journal of Antimicrobial Agents|July 3, 2017
Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' windowCristina Miglis, Nathaniel J Rhodes, Joseph L Kuti, et al.
Infection Control and Hospital Epidemiology|May 14, 2016
Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption MetricsNathaniel J Rhodes, Jamie L Wagner, Elise M Gilbert, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2006
Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stayKimberly K Scarsi, Joe M Feinglass, Marc H Scheetz, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2007
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumanniiMarc H Scheetz, Chao Qi, John R Warren, et al.
Clinical Pharmacology and Therapeutics|June 11, 2026
Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug DosingMarc H Scheetz, Thomas P Lodise, Nathaniel J Rhodes, et al.
Genome Announcements|March 12, 2016
Genome Sequences of Five Clinical Isolates of Klebsiella pneumoniaeL Letti Lopez, Brigida Rusconi, Heidi Gildersleeve, et al.
Diagnostic Microbiology and Infectious Disease|July 4, 2017
Factors contributing to vancomycin-resistant Enterococcus spp. horizontal transmission events: exploration of the role of antibacterial consumptionElise M Gilbert, Teresa R Zembower, Nathaniel J Rhodes, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 30, 2015
An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicityNathaniel J Rhodes, Joseph L Kuti, David P Nicolau, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2015
Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the HorseNathaniel J Rhodes, J Nicholas O'Donnell, Bryan D Lizza, et al.
Pageof 23